# Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

> **NCT00050999** · PHASE4 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 195 (—)

## Conditions studied

- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides
- Sezary Syndrome

## Interventions

- **DRUG:** ONTAK

## Key facts

- **NCT ID:** NCT00050999
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-06
- **Primary completion:** 2006-09
- **Final completion:** 2006-12
- **Target enrollment:** 195 (—)
- **Last updated:** 2008-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050999, "Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00050999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*